Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Graf

Showing results (211-220 of 247) with videos related to

Pageof 25
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2025
Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate CancerNicolas Sayegh, Ryon P Graf, Umang Swami, et al.
JAMA Network Open|June 24, 2026
Bone-Modifying Agents in Metastatic Castration-Resistant Prostate CancerZeynep Irem Ozay, Yeonjung Jo, Georges Gebrael, et al.
Plos One|November 17, 2016
Chromosomal Instability Estimation Based on Next Generation Sequencing and Single Cell Genome Wide Copy Number Variation AnalysisStephanie B Greene, Angel E Dago, Laura J Leitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2024
Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World PracticeDebra L Richardson, Julia C F Quintanilha, Natalie Danziger, et al.
Journal of Circulating Biomarkers|September 23, 2017
Detection and Characterization of Circulating Tumour Cells from Frozen Peripheral Blood Mononuclear CellsDavid Lu, Ryon P Graf, Melissa Harvey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 14, 2025
Correction: Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World PracticeDebra L Richardson, Julia C F Quintanilha, Natalie Danziger, et al.
JAMA Oncology|June 5, 2016
Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate CancerHoward I Scher, David Lu, Nicole A Schreiber, et al.
Biomaterials Science|September 14, 2022
Multidomain peptide hydrogel adjuvants elicit strong bias towards humoral immunityBrett H Pogostin, Marina H Yu, Alon R Azares, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 28, 2017
Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse SurvivalDaniel J Boffa, Ryon P Graf, Michelle C Salazar, et al.
European Urology|October 30, 2021
Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate CancerRyon P Graf, Virginia Fisher, Joaquin Mateo, et al.
Pageof 25

Showing results (211-220 of 247) with videos related to

Sort By:
Pageof 25
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2025
Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate CancerNicolas Sayegh, Ryon P Graf, Umang Swami, et al.
JAMA Network Open|June 24, 2026
Bone-Modifying Agents in Metastatic Castration-Resistant Prostate CancerZeynep Irem Ozay, Yeonjung Jo, Georges Gebrael, et al.
Plos One|November 17, 2016
Chromosomal Instability Estimation Based on Next Generation Sequencing and Single Cell Genome Wide Copy Number Variation AnalysisStephanie B Greene, Angel E Dago, Laura J Leitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2024
Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World PracticeDebra L Richardson, Julia C F Quintanilha, Natalie Danziger, et al.
Journal of Circulating Biomarkers|September 23, 2017
Detection and Characterization of Circulating Tumour Cells from Frozen Peripheral Blood Mononuclear CellsDavid Lu, Ryon P Graf, Melissa Harvey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 14, 2025
Correction: Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World PracticeDebra L Richardson, Julia C F Quintanilha, Natalie Danziger, et al.
JAMA Oncology|June 5, 2016
Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate CancerHoward I Scher, David Lu, Nicole A Schreiber, et al.
Biomaterials Science|September 14, 2022
Multidomain peptide hydrogel adjuvants elicit strong bias towards humoral immunityBrett H Pogostin, Marina H Yu, Alon R Azares, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 28, 2017
Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse SurvivalDaniel J Boffa, Ryon P Graf, Michelle C Salazar, et al.
European Urology|October 30, 2021
Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate CancerRyon P Graf, Virginia Fisher, Joaquin Mateo, et al.
Pageof 25